Catheter-associated UTI & catheter biofilm
Catheter-associated urinary tract infection (CAUTI) is the most common healthcare-associated infection, driven by uropathogens—chiefly Escherichia coli and Proteus mirabilis—that colonize the indwelling catheter surface and build resilient biofilms. Proteus biofilms are especially damaging because its urease alkalinizes urine, precipitating struvite and apatite into crystalline encrustations that block catheters and shield bacteria from antibiotics and host defenses. Because biofilm-embedded organisms tolerate antibiotics at 100–1000x the planktonic MIC and CAUTI pathogens are increasingly multidrug-resistant, conventional therapy often fails without catheter exchange. Lytic bacteriophages are well suited here: they self-amplify at the infection site, many encode polysaccharide depolymerases that degrade the biofilm matrix, they can be impregnated into catheter materials for prevention, and—being delivered topically into the bladder or catheter—they reach high local titers with a favorable safety profile.
How phages act here
Mechanism
Phages bind strain-specific surface receptors (LPS, capsule, flagella, or pili) on E. coli and P. mirabilis, inject their genome, replicate, and lyse the host—killing being density-dependent and self-propagating as long as susceptible bacteria remain. Against biofilm, virion-associated or phage-encoded depolymerases (e.g., a peptidoglycan-hydrolase/tailspike domain identified in P. mirabilis phage vB_PmiA_PM1) digest exopolysaccharide and let phage penetrate deeper layers; on Foley catheters this reduces P. mirabilis and E. coli biofilm and encrustation/crystalline blockage. Because any single phage has a narrow host range and bacteria mutate receptors, cocktails of complementary phages are used to broaden coverage and suppress resistance, and phages frequently show phage-antibiotic synergy (sub-MIC antibiotics enhance lysis; receptor-loss escape mutants can resensitize to antibiotics). The most advanced engineered angle is CRISPR-Cas3: Locus Biosciences' LBP-EC01 arms E. coli phages with a Cas3 payload that shreds the host chromosome, boosting killing potency and lethality over the natural phages.
Where it stands
Current evidence
Evidence spans rigorous in vitro/catheter-model work plus early human trials, but no phage product is yet approved for CAUTI specifically. Foundational benchtop work (Carson 2010) showed lytic phages cut established P. mirabilis and E. coli catheter biofilms by 3–4 log (99.9–99.99%) and that hydrogel Foley catheters impregnated with phage reduced biofilm formation ~90%. A P. mirabilis two-phage cocktail (Mirzaei 2022) reduced biofilm mass ~65% and lowered catheter encrustation in a phantom-bladder model, and a 2026 P. mirabilis phage study (Gomaa, vB_PmiA_PM1) confirmed biofilm/swarming disruption on silicone catheters while flagging that efficacy drops markedly in artificial urine vs rich media—a key translational caveat. In humans, the landmark intravesical Pyophage RCT in TURP patients (Leitner 2020, Lancet Infect Dis, NCT03140085) found phages non-inferior to antibiotics and safe, though not superior to placebo bladder irrigation. The most advanced program is the engineered CRISPR-Cas3 cocktail LBP-EC01 (Locus Biosciences); Part 1 of the phase 2 ELIMINATE trial (Kim 2024, Lancet Infect Dis, NCT05488340), funded by BARDA, showed rapid, durable E. coli reduction in urine and full symptom resolution by day 10 in evaluable uncomplicated-UTI patients, with the controlled Part 2 underway. Most CAUTI/Proteus-specific data remain preclinical; human phage use for catheter biofilm is still largely compassionate-use/case-level plus UTI-broad trials.
Evidence confidence: medium
The data
Key studies & trials
- Carson L, Gorman SP, Gilmore BF. The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol. 2010;59(3):447-455. ↗
- Mirzaei A, Wagemans J, Nasr Esfahani B, Lavigne R, Moghim S. A Phage Cocktail To Control Surface Colonization by Proteus mirabilis in Catheter-Associated Urinary Tract Infections. Microbiol Spectr. 2022;10(5):e02092-22. ↗
- Leitner L, Ujmajuridze A, Chanishvili N, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21(3):427-436. (NCT03140085) ↗
- Kim P, Sanchez AM, Penke TJR, et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Lancet Infect Dis. 2024;24(12):1319-1332. (NCT05488340) ↗
Who is working on it
Programs & centers
The possibility
The near-term vision is a catheter that fights back: silicone or hydrogel Foley catheters pre-loaded with phage cocktails (and depolymerases) that prevent E. coli and Proteus colonization at the source, paired with on-demand bladder instillations of personalized cocktails matched to a patient's isolate by rapid phage-susceptibility testing. Engineered CRISPR-Cas3 phages like LBP-EC01 hint at a future where a single intelligently designed cocktail clears antibiotic-resistant biofilm without a catheter swap, turning a recurrent, blockage-prone infection into a manageable outpatient treatment. If the ELIMINATE program and parallel Proteus cocktails translate, phage-antibiotic combinations could become a frontline, resistance-sparing tool precisely where antibiotics fail most—on the biofilm-encased surface of an indwelling device.